Rebecca J. Deyell

Rebecca J. Deyell

Auto-generated profile, based on publicly available information

Rebecca J. Deyell

Division of Pediatric Hematology/Oncology, BC Children's Hospital and Research Institute University of British Columbia Vancouver British Columbia Canada

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2016 in American Journal of Surgical Pathology
Verified
Journal Article
Closed access
AAAli H. Alassiri
Ali H. Alassiri
RARola H. Ali
Rola H. Ali
YSYaoqing Shen
Yaoqing Shen
ALAmy Lum
Amy Lum
CSCaron Strahlendorf
Caron Strahlendorf
TNTony L. Ng
Tony L. Ng
Inflammatory myofibroblastic tumor (IMT) is a genetically heterogenous tumor of the viscera and soft tissues, with multiple molecular features having been demonstrated in this tumor type. About 50% of cases harbor an anaplastic lymphoma kinase (ALK) gene rearrangement, and recent studies have described novel fusions involving the ROS1 and PDGFRβ genes in a subset of ALK-negative cases. However, the molecular features of the remaining subset of cases are not yet defined. We report a case of a large, highly aggressive IMT of the lung in a 17-year-old girl. This case was molecularly characterized through whole-genome and transcriptome sequencing. Subsequently, we investigated a cohort of 15 ALK-negative IMTs of various anatomic sites. All cases were screened using fluorescence in situ hybridization (FISH) for rearrangement of the ETV6 locus and with reverse transcription polymerase chain reaction (RT-PCR) for the ETV6-NTRK3 fusion transcript. Whole-genome and transcriptome sequencing revealed an ETV6-NTRK3 fusion transcript in our index case. This was confirmed by FISH studies for ETV6 gene rearrangement, as well as by RT-PCR. In addition, 2 additional cases in our cohort demonstrated ETV6 rearrangement by FISH. The presence of ETV6-NTRK3 fusion transcript was demonstrated by RT-PCR in one of these additional cases. In summary, we demonstrate the expression of the ETV6-NTRK3 fusion oncogene in a small subset of IMTs, lending further support to the role of oncogenic tyrosine kinases in the pathophysiology of this tumor type. Our data also further expand the growing spectrum of tumor types expressing the ETV6-NTRK3 fusion.

28 July 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMiguel Alcaide
Miguel Alcaide
MCMatthew Cheung
Matthew Cheung
JHJack Hillman
Jack Hillman
SRShahrad Rod Rassekh
Shahrad Rod Rassekh
RDRebecca J. Deyell
Rebecca J. Deyell
RMRyan D. Morin
Ryan D. Morin
Cell-free DNA (cfDNA) has become a comprehensive biomarker in the fields of non-invasive cancer detection and monitoring, organ transplantation, prenatal genetic testing and pathogen detection. While cfDNA samples can be obtained using a broad variety of approaches, there is an urgent need to standardize analytical tools aimed at assessing its basic properties. Typical methods to determine the yield and fragment size distribution of cfDNA samples are usually either blind to genomic DNA contamination or the presence of enzymatic inhibitors, which can confound and undermine downstream analyses. Here, we present a novel droplet digital PCR assay to identify suboptimal samples and aberrant cfDNA size distributions, the latter typically associated with high levels of circulating tumour DNA (ctDNA). Our assay was designed to promiscuously cross-amplify members of the human olfactory receptor (OR) gene family and includes a customizable diploid locus for the determination of absolute cfDNA concentrations. We demonstrate here the utility of our assay to estimate the yield and quality of cfDNA extracts and deduce fragment size distributions that correlate well with those inferred by capillary electrophoresis and high throughput sequencing. The assay described herein is a powerful tool to establish quality controls and stratify cfDNA samples based on presumed ctDNA levels, then facilitating the implementation of robust, cost-effective and standardized analytical workflows into clinical practice.

24 September 2015 in Cold Spring Harbor Molecular Case Studies
Verified
Journal Article
Open access
PDF file
JLJanessa Laskin
Janessa Laskin
SJSteven Jones
Steven Jones
SASamuel Aparicio
Samuel Aparicio
SCStephen Chia
Stephen Chia
CCCarolyn Ch'Ng
Carolyn Ch'Ng
MMMarco Marra
Marco Marra
Given the success of targeted agents in specific populations it is expected that some degree of molecular biomarker testing will become standard of care for many, if not all, cancers. To facilitate this, cancer centers worldwide are experimenting with targeted “panel” sequencing of selected mutations. Recent advances in genomic technology enable the generation of genome-scale data sets for individual patients. Recognizing the risk, inherent in panel sequencing, of failing to detect meaningful somatic alterations, we sought to establish processes to integrate data from whole-genome analysis (WGA) into routine cancer care. Between June 2012 and August 2014, 100 adult patients with incurable cancers consented to participate in the Personalized OncoGenomics (POG) study. Fresh tumor and blood samples were obtained and used for whole-genome and RNA sequencing. Computational approaches were used to identify candidate driver mutations, genes, and pathways. Diagnostic and drug information were then sought based on these candidate “drivers.” Reports were generated and discussed weekly in a multidisciplinary team setting. Other multidisciplinary working groups were assembled to establish guidelines on the interpretation, communication, and integration of individual genomic findings into patient care. Of 78 patients for whom WGA was possible, results were considered actionable in 55 cases. In 23 of these 55 cases, the patients received treatments motivated by WGA. Our experience indicates that a multidisciplinary team of clinicians and scientists can implement a paradigm in which WGA is integrated into the care of late stage cancer patients to inform systemic therapy decisions.

13 September 2013 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
YMYaël P. Mossé
Yaël P. Mossé
RDRebecca J. Deyell
Rebecca J. Deyell
FBFrank Berthold
Frank Berthold
ANAkira Nagakawara
Akira Nagakawara
PAPeter Ambros
Peter Ambros
KMKatherine K. Matthay
Katherine K. Matthay

1 May 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ADAnirban Das
Anirban Das
UTUri Tabori
Uri Tabori
LNLauren C. Sambira Nahum
Lauren C. Sambira Nahum
NCNatalie B. Collins
Natalie B. Collins
RDRebecca Deyell
Rebecca Deyell
DMDaniel Morgenstern
Daniel Morgenstern
Purpose: Checkpoint inhibitors have limited efficacy for children with unselected solid and brain tumors. We report the first prospective pediatric trial (NCT02992964) using nivolumab exclusively for refractory nonhematologic cancers harboring tumor mutation burden (TMB) ≥5 mutations/megabase (mut/Mb) and/or mismatch repair deficiency (MMRD). Patients and Methods: Twenty patients were screened, and 10 were ultimately included in the response cohort of whom nine had TMB >10 mut/Mb (three initially eligible based on MMRD) and one patient had TMB between 5 and 10 mut/Mb. Results: Delayed immune responses contributed to best overall response of 50%, improving on initial objective responses (20%) and leading to 2-year overall survival (OS) of 50% [95% confidence interval (CI), 27–93]. Four children, including three with refractory malignant gliomas are in complete remission at a median follow-up of 37 months (range, 32.4–60), culminating in 2-year OS of 43% (95% CI, 18.2–100). Biomarker analyses confirmed benefit in children with germline MMRD, microsatellite instability, higher activated and lower regulatory circulating T cells. Stochastic mutation accumulation driven by underlying germline MMRD impacted the tumor microenvironment, contributing to delayed responses. No benefit was observed in the single patient with an MMR-proficient tumor and TMB 7.4 mut/Mb. Conclusions: Nivolumab resulted in durable responses and prolonged survival for the first time in a pediatric trial of refractory hypermutated cancers including malignant gliomas. Novel biomarkers identified here need to be translated rapidly to clinical care to identify children who can benefit from checkpoint inhibitors, including upfront management of cancer. See related commentary by Mardis, p. 4701

2 October 2019 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
OVOlena M. Vaske
Olena M. Vaske
IBIsabel Bjork
Isabel Bjork
SSSofie Reda Salama
Sofie Reda Salama
HBHolly Beale
Holly Beale
ASAvanthi Tayi Shah
Avanthi Tayi Shah
DHDavid Haussler
David Haussler
We present a framework for comparative RNA sequencing (RNA-Seq) analysis of pediatric tumors across multiple precision medicine studies. Our framework uses public genomic data sets of more than 11 000 tumor RNA-Seq samples that we consolidated and released to the community. We describe an application of our framework and the data compendium to the analysis of 144 tumors from children and young adults with a relapsed, refractory, or rare cancer, studied on 4 separate precision medicine trials in the United States and Canada.